EP Patent

EP3678670A1 — Neuroactive steroids and their methods of use

Assigned to Sage Therapeutics Inc · Expires 2020-07-15 · 6y expired

What this patent protects

The present invention relates to a compound (I), pharmaceutically acceptable salts or pharmaceutically acceptable compositions thereof for the treatment of CNS related disorders, for example tremors, for example essential tremor; the Depression ; and anxiety disorders, as well as…

USPTO Abstract

The present invention relates to a compound (I), pharmaceutically acceptable salts or pharmaceutically acceptable compositions thereof for the treatment of CNS related disorders, for example tremors, for example essential tremor; the Depression ; and anxiety disorders, as well as methods for improving the efficacy of administering Compound 1 for treating said CNS-related disorders. The invention also relates to methods for increasing the bioavailability of a Compound 1 or pharmaceutically acceptable salts or pharmaceutically acceptable compositions thereof.

Drugs covered by this patent

Patent Metadata

Patent number
EP3678670A1
Jurisdiction
EP
Classification
—
Expires
2020-07-15
Drug substance claim
No
Drug product claim
No
Assignee
Sage Therapeutics Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.